CurrentEndo
Get Weekly

Topic · page 11 of 119

Type 2 & other diabetes

Type 2 diabetes and prediabetes: prevention, remission, glucose-lowering drugs, weight-based treatment, insulin, lifestyle and diet; monogenic and other specific types of diabetes

Briefs 401–440 of 4,758 placed here, newest publication first

Briefs in Type 2 & other diabetes

Newest publication first

  1. Diabetes Obes Metab

    Glycemic Normalization Immediately Following Vertical Sleeve Gastrectomy in Adolescents With Type 2 Diabetes From the ST 2 OMP Study

    Cohort study

  2. Diabetes Obes Metab

    Incidence and Associated Factors of Hypertension and Dyslipidemia Improvement in People With Type 2 Diabetes Remission: A Multicenter Real‐World Retrospective Cohort Study (JDDM84)

    Cohort study

  3. Diabetes Obes Metab

    Optic Ischaemic Neuropathy in Incretin‐Based Therapy: A Comparative Analysis of Real‐World Safety Data

    Research article

  4. J Clin Endocrinol Metab

    Pancreatic fat and the risk of future dysglycemia: a systematic review and meta-analysis

    Meta-analysis

  5. Diabetes Obes Metab

    Perioperative Desaturation and Postoperative Nausea or Vomiting Requiring Antiemetic Administration in Glucagon‐Like Peptide‐1 Receptor Agonist Users Undergoing Ambulatory Ophthalmic Surgery Under Mild‐To‐Moderate Sedation: A Large Retrospective Cohort Study

    Cohort study

  6. Lancet Diabetes Endocrinol

    Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

    Randomized controlled trial

  7. Lancet Diabetes Endocrinol

    Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

    Randomized controlled trial

  8. Lancet

    Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

    Randomized controlled trial

  9. Diabetes Care

    Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial

    Secondary analysis

  10. NEJM Evid

    HTD1801 in Combination with Metformin for Type 2 Diabetes

    Randomized controlled trial

  11. Lancet

    Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

    Randomized controlled trial

  12. Diabetes Res Clin Pract

    Prediabetes in Ontario: improving surveillance for better disease prevention

    Cohort study

  13. Diabetologia

    Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages

    Cross-sectional study

  14. Diabetologia

    Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial

    Randomized controlled trial

  15. Diabet Med

    Diabetes, in‐hospital mortality trends and life expectancy loss among a 21.8‐million population in Beijing, China, 2012–2024

    Cohort study

  16. Diabetes Res Clin Pract

    Fat–muscle balance and incident diabetes: evidence from Chinese and UK cohorts

    Cohort study

  17. Endocr Pract

    Real-World Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Combination Therapy on Weight Management Within a Digital-Supported Shared Care Model for Type 2 Diabetes

    Cohort study

  18. Diabetologia

    Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes

    Cohort study

  19. Int J Obes (Lond)

    Triglyceride-glucose index trajectories and the incident risk of type 2 diabetes mellitus in Chinese adults with normal weight: the China-PAR project

    Cohort study

  20. Diabetes Obes Metab

    Associations of Fasting Glucagon and the Glucagon–Alanine Index With Hepatic Steatosis and Liver Stiffness in Japanese Individuals With Type 2 Diabetes

    Cross-sectional study

  21. Cardiovasc Diabetol

    Association of 14 triglyceride-glucose (TyG)-related indices with new-onset cardiovascular disease in middle-aged and older adults: evidence from the CHARLS and ELSA aging cohorts

    Cohort study

  22. Diabetes Res Clin Pract

    Attenuating the mortality risk of socioeconomic deprivation in type 2 diabetes: Minimum and compensatory physical activity estimates

    Cohort study

  23. Diabetes Obes Metab

    Association of Post‐Oral Glucose Tolerance Test Hypoglycaemia With Clinical Features, Incident Diabetes and Mortality in the Di@bet.es Cohort

    Cohort study

  24. Diabetes Obes Metab

    Glucagon‐Like Peptide‐1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study

    Cohort study

  25. Diabetes Obes Metab

    Molecular Signature of Prediabetes With High‐Risk of Diabetes Revealed by Deep Plasma Proteome

    Cohort study

  26. Diabetes Obes Metab

    Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

    Randomized controlled trial

  27. Diabetes Obes Metab

    Projecting the Macroeconomic Burden of Type 2 Diabetes Mellitus Attributable to High Body‐Mass Index in Southeast Asia: A Bayesian Productivity‐Adjusted Life Years Approach Based on Global Burden of Diseases 2023

    Cohort study

  28. Diabetes Obes Metab

    Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

    Cohort study

  29. Endocr Pract

    Beyond Hospital Readmissions: A Multifaceted Insulin-Centered Diabetes Education Approach Impacts Contemporary Acute Care Outcomes and Prolongs Home Time

    Mechanistic study

  30. Cardiovasc Diabetol

    Effects of adiposity, insulin resistance, and inflammation on cardiometabolic multimorbidity: insights from interaction analyses and metabolic phenotyping in the China health and retirement longitudinal study 2011–2018

    Cohort study

  31. Diabetes Obes Metab

    Cost‐Effectiveness of NT ‐ proBNP –Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank

    Cohort study

  32. Diabetes Obes Metab

    Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

    Cohort study

  33. Diabetes Obes Metab

    Heterogeneity of Treatment Effects Across Nine Glucose‐Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND ‐ T2DM Network Study

    Cohort study

  34. Diabetes Obes Metab

    Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

    Randomized controlled trial

  35. Diabetes Care

    Progression to Diabetes by Adults With Prediabetes Who Use the National Diabetes Prevention Program: A Natural Experiment

    Cohort study

  36. Cardiovasc Diabetol

    Unraveling ‘F’ factor: towards a genetic-clinical framework for the musculoskeletal-heart crosstalk in metabolic aging

    Cohort study

  37. Cardiovasc Diabetol

    Estimated glucose disposal rate outperforms thirteen other insulin resistance indices in predicting new-onset cardiometabolic multimorbidity: a longitudinal study from the china health and retirement longitudinal study (CHARLS) and cross-sectional replication from the national health and nutrition examination survey (NHANES)

    Cross-sectional study

  38. Diabetes Obes Metab

    Acute GIP and GLP ‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

    Randomized controlled trial

  39. Diabetes Obes Metab

    Greater Glycaemic Responses to Bodyweight Change in South Asians Than White Europeans at High Risk of Type 2 Diabetes

    Secondary analysis

  40. JAMA Netw Open

    HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial

    Randomized controlled trial

All 4,758 Briefs in ExploreShowing Briefs 401–440 of 4,758, newest first